| 15 11 2012|
TOP srl announces a collaboration with Charles River Laboratories International Inc. for the marketing and sales in North America (USA and Canada) of its products.
Lodi, Italy, November 14, 2012. TOP (Transgenic Operative Products) srl announced that it has signed an important agreement to promote and market 3 of its products in North America (U.S. and Canada) with Charles River Laboratories International, Inc. (NYSE: CRL), a world leader provider of models for biological research and pharmaceutical industry.
Under this agreement, Charles River has become the exclusive supplier for North America of three TOP srl products, licensed products will maintain their original brand (repTOP™) and TOPsrl. This agreement will allow the TOPsrl access to the North American biotechnology market through an extensive sales network.
TOP models marketed in North America by Charles River are the following:
- repTOP™mitoIRE for researching proliferative effects in oncology, regenerative medicine and toxicology.
- repTOP™ ERE-Luc for assessing stimulation and activity of the estrogen receptors, with primary area of research in reproductive functions and dysfunctions, menopause and related diseases, and hormone regulated neurological disorders (depression and neurodegeneration)
- repTOP™PPRE-Luc for the study of peroxisome proliferation in diabetes, arteriosclerosis, inflammation, lipid metabolism disorders and cardiovascular disease
TOP (Transgenic Operative Products) srl, is a research biotech company originated from the University of Milan, Italy, backed by an important Italian Venture Capital Firm (NEXT fund managed by Finlombarda Gestioni SGR) and collaborating with major pharmaceutical and biotechnology organizations. TOP is located at the Parco Tecnologico Padano in Lodi, near Milan (Italy).
Using superior technology developed at the University of Milan in the laboratories of Dr. Adriana Maggi, luciferase genes (the reporter) have been engineered to be under the control of three different promoters which allow the in vivo imaging of physiological and pathological processes using a non-invasive technique. Coupled with a low signal to noise ratio, good reproducibility and high specificity, these models offer a versatile way to quantitatively assess both endogenous processes, such as estrogen receptor activity during the estrous cycle (repTOP™ERE-Luc), toxicological/pathological end points such as tumor development over time (repTOP™mitoIRE) or studying the role of Peroxisome Proliferator Activated Receptors (PPARs) in Amytrophic Lateral Sclerosis by crossing with hSOD1G93A mice (repTOP™PPRE-Luc).
More than 40 publications in main scientific journals (e.g. Nature Reviews Drug Discovery, Nature Medicine, PNAS, TIPS) testimony the quality of the repTOP™ reporter mice technology.
The non-invasive nature of the bioluminescent read-out allows for multiple read-outs for both short term and long term studies in the same animal thus minimizing inter-animal variation and potentially using fewer animals per study. In some case, such as in the induction of skin cancer, the animal can act as their own control with vehicle being administered on one side and the tumorigenic agent on the other.